Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Vycellix, Inc. is an American private company located in Tampa, FL. The firm operates as a biopharmaceutical company. Evren Alici is currently the CEO of the firm.\nThe company says this about itself: Vycellix is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and natural killer (NK) cell-based cancer therapies.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare providers to treat cancer patients and improve their lives.

Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.

Centre Hospitalier Universitaire Vaudois (doing business as Lausanne University Hospital) is a private company headquartered in Lausanne, Switzerland, that operates university hospitals.\nThe company says this about itself: The CHUV, Lausanne University Hospital, is one of the five university hospitals in Switzerland. With its 16 clinical and medico-technical departments and their numerous services, the CHUV is renowned for its academic achievements in health care, research, and teaching. The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). The CHUV has been recognized as one of the World?s 10 best hospitals according to the 2021 ranking of Newsweek magazine. It is with enthusiasm, that the Chairman of the Department of Urology, Prof Beat Roth, will pursue and support the research and studies with this novel treatment for bladder cancer.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer. The company's Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-1400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Taiga Biotechnologies lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient’s own immune cells to help fight against cancer and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. They developing technologies to generate red blood cells in the laboratory for clinical applications and products to improve the utility of red blood cell products.

BioGenes Gesellschaft f��r Biopolymere mbH specializes in the development and production of customized immunoassays, antigens and antibodies. The firm focused on the ELISA development, validation and kit production. It services include biotinylation of antibodies and search of suitable antibody pairs, testing of cross reactivities against various proteins, optimization of assay parameters including plate-coating conditions and buffers, determination of analytical assay parameters, production of complete kits or assay components in agreed quality and quantity and stability testing of the kits or assay components, permanent quality control of all components. The firm provides additionally the business develops custom host cell protein assays, include project design and management in cooperation with the customer, in-house antibody development and characterization with 2D analysis, ELISA and Western Blot and development of HCP assays in buffer solution and working matrices. The company was founded in 1992 and is headquartered in Berlin, Germany.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Hansa Biopharma is a biopharmaceutical company that develops immunomodulatory treatments for people living with rare immunological diseases. They concentrate on creating novel, life-saving and life-changing treatments that can meet the critical, unmet medical needs of individuals with uncommon immunological disorders. To target pathogenic or disease-causing antibodies, they developed its proprietary antibody-cleaving enzyme technology platform. The company's diverse therapeutic pipeline has the potential to address significant unmet medical needs in transplantation, autoimmune diseases, gene therapy, and oncology indications.

Cellvie, Inc. is a company headquartered in the United States involved in biological products, except diagnostic substances.